Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from acro
Almost half of UK doctors would not use generative artificial intelligence (GenAI) to treat patients, although there is greater willingness to use it for diagnostic purposes.